Graft versus Host Disease
FDA Approves First Oral Liquid Imatinib for Leukemia and Other Cancers
Imatinib oral solution has gained FDA approval for the treatment of some cancers, including certain forms of leukemia.
Read More
Learning From a Multidisciplinary Approach in Graft-Vs-Host Disease
In this feature, Memorial Sloan Kettering Cancer Center physicians explain what drives the collaborative process in their multidisciplinary graft-vs-host disease clinic.
Advancements in Follicular Lymphoma Treatment With Targeted Therapies
At the 42nd Annual Chemotherapy Foundation Symposium, Erin Mulvey, MD, discussed the significant progress being made in the treatment of relapsed or refractory follicular lymphoma.
Nivolumab-Chemotherapy Combo Boosts PFS in cHL, Poised for Standard Use
The N-AVD regimen showed improved progression-free survival and lower toxicity than BV-AVD in advanced Hodgkin lymphoma, particularly benefiting patients 60 and older.
Luspatercept, Improved Diagnostics Deliver in MDS
“We have seen a number of dynamic changes in MDS over the last few years, and integrating them into our treatment paradigm will impact our approach, and perhaps offer a glimpse into the future."
Investigational Studies in MDS: Exploring Promising Therapies
David Sallman, MD, discussed the challenges and new studies of high-risk myelodysplastic syndrome therapies.
